Zero ad trackers.We never sell your data.Healthcare professional?Clinician Resources
Home/Rare Diseases/Pulmonary Alveolar Proteinosis

Pulmonary & Respiratory

Pulmonary Alveolar Proteinosis (PAP) Clinical Trials

Also called PAP, Autoimmune Pulmonary Alveolar Proteinosis, aPAP, Autoimmune PAP, Alveolar Proteinosis, GM-CSF Autoantibody Disease, Hereditary PAP

The air sacs of the lungs are coated with surfactant, an oily film that keeps them from collapsing. Cleanup cells called alveolar macrophages constantly remove the used surfactant, but they only do that job when a signal protein called GM-CSF tells them to.

In plain words, pulmonary alveolar proteinosis is a rare lung disease where a soapy substance builds up inside the tiny air sacs of the lungs. Cleanup cells meant to clear it away stop working, so breathing slowly gets harder over time.

Get an email when new Pulmonary Alveolar Proteinosis trials open or the FDA decides. Get alerts

Pulmonary Alveolar Proteinosis

Where treatments stand, from ClinicalTrials.gov and FDA labels

Also 2 studies with no phase, like observational studies.

FDA review0

No decision pending. FDA calendar

FDA-approved medicines0

No medicine's current FDA label names Pulmonary Alveolar Proteinosis yet.

Pulmonary Alveolar Proteinosis has no FDA-approved medicines, 6 open or active clinical trials (4 recruiting), and no pending FDA decision.

Labels checked October 21, 2026.Download the data

Latest for Pulmonary Alveolar Proteinosis

See all trialsThe week in rare disease

Each date is the day a change was posted. Open an item to see where things stand now.

More about Pulmonary Alveolar Proteinosis

In autoimmune PAP, the immune system makes antibodies that bind to GM-CSF and block it. The macrophages fall silent, surfactant piles up, and the air sacs slowly fill with a sludge that keeps air from getting in and oxygen from crossing into the blood. The same loss of GM-CSF weakens the macrophages' ability to fight germs, so lung infections are more common.

Keep reading about Pulmonary Alveolar Proteinosis

On a CT scan the lungs show a pattern doctors call crazy paving: patches of haze crossed by fine lines. That pattern raises suspicion but does not prove PAP, and a bronchoscopy can confirm surfactant buildup without saying which type of PAP it is. The test that settles the autoimmune form is a blood test for the GM-CSF autoantibody, which the PAP Foundation describes as 100% sensitive and specific.

Savara, the company developing molgramostim, runs a program called aPAP ClearPath through which doctors can order the blood test for eligible patients at no charge to the patient, the doctor or insurers. No one knows what sets the autoimmune process off, and about 5-7% of people improve on their own.

For people who need treatment, the standard is whole lung lavage. Under general anesthesia, one lung is kept breathing on a ventilator while the other is washed with saline to flush the surfactant out. Some people need it once, others every year or so, and a few need it monthly. NORD says most people with autoimmune PAP respond very well to it. Each session is done under general anesthesia that often lasts 3 to 6 hours, and the PAP Foundation describes days in the hospital and 1 to 2 weeks of recovery pain after each one.

What are the symptoms of Pulmonary Alveolar Proteinosis?

These are common symptoms of Pulmonary Alveolar Proteinosis, and how strong they are varies from person to person.

  • Shortness of breath that creeps in slowly, first with activity and later at rest
  • A cough that is dry or brings up whitish phlegm
  • Tiredness and a reduced ability to exercise, such as being winded on a flight of stairs
  • Bluish fingertips from low blood oxygen as the disease progresses
  • Fever, chest pain or blood-streaked phlegm, usually a sign of a lung infection on top of PAP
  • No symptoms at all in about 3 in 10 people at any given time, with the disease sometimes found by accident

Who gets Pulmonary Alveolar Proteinosis?

Autoimmune PAP most often appears in adults between 30 and 40, though it has been diagnosed in children as young as 3. It is more common in men, and smokers are affected more often, which suggests cigarette smoke can act as a trigger. The hereditary form, caused by changes in the genes for the GM-CSF receptor, usually shows up in children under 10. Because the symptoms resemble asthma or pneumonia, the PAP Foundation says it is often misdiagnosed at first, and Savara says an accurate diagnosis is delayed by 18 months on average.

Next steps: find trials you might fitsee what is being testedget help payingget alerts

Which new Pulmonary Alveolar Proteinosis medicines are in trials?

Investigational medicines Trial Friend tracks for Pulmonary Alveolar Proteinosis, with trial results, safety findings and where each one stands.

How to get help paying for Pulmonary Alveolar Proteinosis treatment

Charity funds and drugmaker programs for Pulmonary Alveolar Proteinosis, checked at the source.

Which insurance do you have? Pick one to see what fits. Tap it again to clear.
Your insurance
Charity funds
  • From a charity · NORD RareCare
    Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Medical Assistance fund
    Open

    Pays for: Medical and medication costs.

    The foundation says: “Accepting new applications and re-enrollments for next year”
Status as each foundation showed it on November 20, 2026.

Open the full patient assistance finder →

Side effects people have reported to the FDA

Side effects people have reported to the FDA

Real-world side effect reports from the FDA Adverse Event Reporting System (FAERS). Includes both FDA-approved drugs and investigational therapies from active clinical trials. Click any drug to see what patients reported.

Loading side effect data...

Diagnosis and genetic testing

How Pulmonary Alveolar Proteinosis is diagnosed

The common autoimmune form is not inherited. A rare hereditary form in children is caused by changes in the genes for the GM-CSF receptor and is diagnosed by genetic testing.

Trusted Pulmonary Alveolar Proteinosis resources

Reputable organizations and medical references for learning more about Pulmonary Alveolar Proteinosis, including disease registries, foundation resources, and clinical guidelines.

Active clinical trials for Pulmonary Alveolar Proteinosis

Use this Pulmonary Alveolar Proteinosis clinical trial finder to see the 4 studies recruiting patients and 2 not yet recruiting in the United States and worldwide, with eligibility criteria in plain English. Of these, 4 test a treatment and 2 are observational studies or registries; each card says which. Every trial comes from ClinicalTrials.gov.

Jump to the trial list, the site map or the pipeline timeline.

Note: Trial recruitment statuses on ClinicalTrials.gov may not immediately reflect recent FDA decisions, sponsor announcements, or enrollment changes. Always confirm a trial's current status directly with the study coordinator before making plans.

6 active trials worldwide
Filter:
Sort:
RecruitingTreatment trialPhase 1/2Recently updatedNCT05761899

Safety and Efficacy of PMT Therapy of hPAP

Intervention: Gene-Corrected Macrophages administered by bronchoscopic instillation

Sponsor: Children's Hospital Medical Center, Cincinnati

The major goal of this study is to evaluate a new type of cell transplantation therapy for individuals with hereditary PAP, study a new treatment that may be useful for treatment of other diseases, and research mechanisms that drive the development and function of lung macrophages.

Ages 18 Years+1 location
Started Jun 2023Updated 1 month agoEst. Jun 2027 (~7 months)
Not yet recruitingTreatment trialPhase 2Recently updatedNCT07890649

A Study of hBMMSC Injection in Patients With aPAP

Intervention: The human Bone Marrow Mesenchymal Stem Cell (hBMMSC) injection, Lactated Ringer's Injection (crystalloid)

Sponsor: Jiuzhitang Maker (Beijing) Cell Technology Co.,Ltd.

The purpose of this multicenter, randomized, double-blind, placebo-controlled phase IIb clinical trial is to evaluate the efficacy and safety of intravenous hBMMSC injection in patients with autoimmune pulmonary alveolar proteinosis (aPAP).

Ages 18 Years+1 location
Expected to start Oct 2026Updated 1 month agoEst. Oct 2029 (~2y 11m)
RecruitingObservational study, no treatment givenNo updates in a whileNCT02461615

A National Registry For Pulmonary Alveolar Proteinosis

Sponsor: Children's Hospital Medical Center, Cincinnati

The major goal of Part A of this study is to establish a National PAP Registry to help make reliable new research tests available to doctors to improve the diagnosis of PAP, increase awareness and knowledge of PAP, and give patients a 'seat at the table' in planning and conductin...

Ages not specified1 location
Started Apr 2015Updated 8 months agoEst. Dec 2030 (~4y 1m)
RecruitingTreatment trialPhase 3No updates in a whileNCT06431776

Inhaled Molgramostim in Pediatric Participants With Autoimmune Pulmonary Alveolar Proteinosis (aPAP).

Intervention: Molgramostim

Sponsor: Savara Inc.

The goal of this open-label study is to study molgramostim as a treatment for autoimmune pulmonary alveolar proteinosis (aPAP) in pediatric patients between age 6 and 18. The main questions it aims to answer are:

Ages 6 Years to 18 Years1 location
Started Oct 2025Updated 9 months agoEst. Jun 2027 (~7 months)
Not yet recruitingTreatment trialPhase 2Hasn't posted an update in over a yearNCT06989333

Local Spraying of GM-CSF Via Bronchoscopy in the Treatment of Autoimmune Pulmonary Alveolar Proteinosis

Intervention: GM-CSF (granulocyte-macrophage colony-stimulating factor)

Sponsor: Jiuwu Bai

This study aims to explore a new therapeutic approach: the feasibility, safety and preliminary efficacy of directly spraying GM-CSF into the airway through bronchoscopy for the treatment of aPAP.

Ages 18 Years to 80 Years
Expected to start Jul 2025Updated 1 year agoEst. Jun 2027 (~7 months)
Find Pulmonary Alveolar Proteinosis trials near you, ranked by distance →
Active trial locations1 city in the US
A study site. Select it to see its trials and get directions. Several sites close together. Select the number to zoom in.

Trial Pipeline

Jan 2021 to Nov 2031
2021
2023
2025
2027
2029
2031
now
Phase 1
Phase 2
Phase 3
Observational
RecruitingNot yet recruitingDelayed startTodayHover a bar for trial details

Read more about Pulmonary Alveolar Proteinosis trials

Need help understanding these trials?
Answers with sources, in plain English
Start withor ask
Run a Pulmonary Alveolar Proteinosis foundation or patient group?
You can put this live trial list on your own website. It updates itself, and it's free.
Get the embed code →

Data from ClinicalTrials.gov, U.S. National Library of Medicine.
Always talk to your doctor before considering a clinical trial.

Pulmonary Alveolar Proteinosis patient communities

Facebook groups, Reddit communities and YouTube channels where Pulmonary Alveolar Proteinosis patients, caregivers and advocacy groups talk.

Pulmonary Alveolar Proteinosis news and guides

Trial Friend articles about Pulmonary Alveolar Proteinosis, newest first

Companies developing Pulmonary Alveolar Proteinosis treatments

Drugmakers that list Pulmonary Alveolar Proteinosis in their rare disease portfolio, 1 in all.

Questions people ask about Pulmonary Alveolar Proteinosis